CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis.
paper
Cited
Public
Unavailable
- Authors
- Leclercq, I A; Farrell, G C; Field, J; Bell, D R; Gonzalez, F J; Robertson, G R
- Year
- 2000
- Journal
- The Journal of clinical investigation
- PMID
- 10772651
- DOI
- 10.1172/JCI8814
- PMCID
- PMC300833
Nonalcoholic steatohepatitis (NASH) and alcoholic liver disease have similar pathological features. Because CYP2E1 plays a key role in alcoholic liver disease with its ability to stimulate lipid peroxidation, we tested the proposal that CYP2E1 could also be a factor in the development of NASH. In a dietary model - mice fed a methionine- and choline-deficient (MCD) diet - liver injury was associated with both induction of CYP2E1 and a 100-fold increase in hepatic content of lipid peroxides. Microsomal NADPH-dependent lipid oxidases contributed to the formation of these lipid peroxides, and in vitro inhibition studies demonstrated that CYP2E1 was the major catalyst. To further define the role of CYP2E1 as an initiator of oxidative stress in NASH, Cyp2e1(-/-)mice were administered the MCD diet. CYP2E1 deficiency neither prevented the development of NASH nor abrogated the increased microsomal NADPH-dependent lipid peroxidation, indicating the operation of a non-CYP2E1 peroxidase pathway. In Cyp2e1(-/-) mice with NASH (but not in wild-type mice), CYP4A10 and CYP4A14 were upregulated. Furthermore, hepatic microsomal lipid peroxidation was substantially inhibited by anti-mouse CYP4A10 antibody in vitro. These results show that experimental NASH is strongly associated with hepatic microsomal lipid peroxidation. CYP2E1, the main enzyme associated with that process in wild-type mice, is not unique among P450 proteins in catalyzing peroxidation of endogenous lipids. We have now identified CYP4A enzymes as alternative initiators of oxidative stress in the liver.
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| CYP2A6 is associated with obesity: studies in human samples and a high fat diet mouse model. | 2019 | 29568101 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| EMMPRIN deficiency alleviated metabolic-associated steatohepatitis progression via regulation of the UBA52-MCT1 axis. | Lai L et al. | β | 2026 | β |
| Orphan drug uttroside B impedes MASH progression and HCC development in experimental models. | Rayginia TP et al. | β | 2026 | β |
| Piperidinesulfonyl derivatives, novel CYP4A inhibitors, ameliorate hepatic lipotoxicity in metabolic dysfunction-associated steatotic liver disease. | Lee M et al. | β | 2026 | β |
| A guide to pathophysiology, signaling pathways, and preclinical models of liver fibrosis. | Sultana M et al. | β | 2025 | β |
| Amelioration of Acetaminophen-Induced Hepatic Oxidative Stress and Inflammation by RNAi Targeting <i>Cyp2e1</i> In Vivo. | Liu W et al. | β | 2025 | β |
| Animal models of lean metabolic dysfunction-associated steatotic liver disease (MASLD): bridging pathogenesis and novel drug discovery. | Papadakos SP et al. | β | 2025 | β |
| Application of small interfering RNA technology in cytochrome P450 gene modulation. | Jiang W et al. | β | 2025 | β |
| Cyclic infusion mitigates liver dysfunction associated with continuous total parenteral nutrition in a novel murine model. | Willis NB et al. | β | 2025 | β |
| Effects of mixed exposure to PFAS on adolescent non-alcoholic fatty liver disease: Integrating evidence from human cohorts, toxicogenomics, and animal models to uncover mechanisms and potential target sites. | Du X et al. | β | 2025 | β |
| Hepatic HKDC1 deletion alleviates western diet-induced MASH in mice. | Xu K et al. | β | 2025 | β |
| Lipoic acid in metabolic dysfunction-associated steatotic liver disease: a review. | Liu F et al. | β | 2025 | β |
| Metabolic Characteristics of Schisantherin B in Mice with Metabolic-Associated Fatty Liver Disease. | Liu FL et al. | β | 2025 | β |
| Single-Nuclei RNA Sequencing Shows the Engagement of PPAR-Delta Target Genes Primarily in Hepatocytes and Cholangiocytes by the Selective PPAR-Delta Agonist Seladelpar. | Yamazaki T et al. | β | 2025 | β |
| Temporal changes of hepatic drug-metabolizing enzymes mediated by hepatic ischemia-reperfusion injury and the protective effect of Oridonin. | Gu T et al. | β | 2025 | β |
| The Expanding Role of GLP-1 Receptor Agonists: Advancing Clinical Outcomes in Metabolic and Mental Health. | Al Qassab M et al. | β | 2025 | β |
| ALDH2 deficiency exacerbates MCD-diet induced MASLD by modulating bile acid metabolism. | Luo J et al. | β | 2024 | β |
| A Review: Cytochrome P450 in Alcoholic and Non-Alcoholic Fatty Liver Disease. | Jiang YJ et al. | β | 2024 | β |
| Emerging mechanisms of lipid peroxidation in regulated cell death and its physiological implications. | Zheng Y et al. | β | 2024 | β |
| Hepatic HKDC1 Deletion Alleviates Western Diet-Induced MASH in Mice | Xu K et al. | β | 2024 | β |
| Human umbilical cord mesenchymal stem cells attenuate diet-induced obesity and NASH-related fibrosis in mice. | Hu J et al. | β | 2024 | β |
| Immunological dynamics in MASH: from landscape analysis to therapeutic intervention. | Rabiu L et al. | β | 2024 | β |
| Interaction between fatty acid oxidation and ethanol metabolism in liver. | Lu Y et al. | β | 2024 | β |
| Liver Antioxidant Capacity and Steatosis in Laying Hens Exposed to Various Quantities of Lupin (<i>Lupinus angustifolius</i>) Seeds in the Diet. | WΓ³jcik M et al. | β | 2024 | β |
| Mechanism of the components compatibility of Scutellariae Radix and Coptidis Rhizoma on mice with hyperlipidemia by regulating the Cyp4a family. | Gao Y et al. | β | 2024 | β |
| Mixed active metabolites of the SNP-6 series of novel compounds mitigate metabolic dysfunction-associated steatohepatitis and fibrosis: promising results from pre-clinical and clinical trials. | Ho HT et al. | β | 2024 | β |
| Notch signaling regulates macrophage-mediated inflammation in metabolic dysfunction-associated steatotic liver disease. | Guo W et al. | β | 2024 | β |
| Primary cilia as a targetable node between biliary injury, senescence and regeneration in liver transplantation. | Esser H et al. | β | 2024 | β |
| Protein restriction associated with high fat induces metabolic dysregulation without obesity in juvenile mice. | Joly A et al. | β | 2024 | β |
| Proteomic and metabolomic analysis of GH deficiency-induced NAFLD in hypopituitarism: insights into oxidative stress. | Zhang Y et al. | β | 2024 | β |
| Reducing Oxidative Stress-Mediated Alcoholic Liver Injury by Multiplexed RNAi of <i>Cyp2e1, Cyp4a10</i>, and <i>Cyp4a14</i>. | Zhang Q et al. | β | 2024 | β |
| The Influence of the FFAR4 Agonist TUG-891 on Liver Steatosis in ApoE-Knockout Mice. | Kiepura A et al. | β | 2024 | β |
| The Synergistic and Opposing Roles of Ο-Fatty Acid Hydroxylase (<i>CYP4A11</i>) and Ο-1 Fatty Acid Hydroxylase (<i>CYP2E1</i>) in Chronic Liver Disease. | Hardwick JP et al. | β | 2024 | β |
| Acetaminophen-Induced Hepatotoxicity in Obesity and Nonalcoholic Fatty Liver Disease: A Critical Review. | Begriche K et al. | β | 2023 | β |
| A Comparative Genomic and Phylogenetic Investigation of the Xenobiotic Metabolism Enzymes of Cytochrome P450 in Elephants Shows Loss in CYP2E and CYP4A. | Watanabe K et al. | β | 2023 | β |
| An update on animal models of liver fibrosis. | Wu S et al. | β | 2023 | β |
| Beneficial Effects of a Curcumin Derivative and Transforming Growth Factor-Ξ² Receptor I Inhibitor Combination on Nonalcoholic Steatohepatitis. | Ha KB et al. | β | 2023 | β |
| Cefminox sodium alleviates the high-fat high-sugar-fed mice's hepatic fatty accumulation via multiple pathways. | Xiao L et al. | β | 2023 | β |
| Customized liver organoids as an advanced <i>in vitro</i> modeling and drug discovery platform for non-alcoholic fatty liver diseases. | Han DW et al. | β | 2023 | β |
| Deficient chaperone-mediated autophagy in macrophage aggravates inflammation of nonalcoholic steatohepatitis by targeting Nup85. | Zhang M et al. | β | 2023 | β |
| Inhibition of mPGES-2 ameliorates NASH by activating NR1D1 via heme. | Zhong D et al. | β | 2023 | β |
| <i>Schisandra</i> lignans ameliorate nonalcoholic steatohepatitis by regulating aberrant metabolism of phosphatidylethanolamines. | Xue L et al. | β | 2023 | β |
| Multi-omics reveals 2-bromo-4,6-dinitroaniline (BDNA)-induced hepatotoxicity and the role of the gut-liver axis in rats. | Deng F et al. | β | 2023 | β |
| Oxidative Stress in Liver Pathophysiology and Disease. | Allameh A et al. | β | 2023 | β |
| Pathogenetic Pathways in Nonalcoholic Fatty Liver Disease: An Incomplete Jigsaw Puzzle. | Pan Q et al. | β | 2023 | β |
| PPARΞ± activation partially drives NAFLD development in liver-specific Hnf4a-null mice. | Kasano-Camones CI et al. | β | 2023 | β |
| Role of ammonia in NAFLD: An unusual suspect. | Thomsen KL et al. | β | 2023 | β |
| Tanshinone I specifically suppresses NLRP3 inflammasome activation by disrupting the association of NLRP3 and ASC. | Zhao J et al. | β | 2023 | β |
| Diet containing dehulled adlay ameliorates hepatic steatosis, inflammation and insulin resistance in rats with non-alcoholic fatty liver disease. | Yeh WJ et al. | β | 2022 | β |
| Impact of L-ornithine L-aspartate on non-alcoholic steatohepatitis-associated hyperammonemia and muscle alterations. | Pichon C et al. | β | 2022 | β |
| In Vivo Analysis of Necrosis and Ferroptosis in Nonalcoholic Steatohepatitis (NASH). | Tsurusaki S et al. | β | 2022 | β |
| Liver Fetuin-A at Initiation of Insulin Resistance. | Lanthier N et al. | β | 2022 | β |
| Lower plasma glutathione, choline, and betaine concentrations are associated with fatty liver in postmenopausal women. | Muzsik-Kazimierska A et al. | β | 2022 | β |
| Mitochondrial Adaptive Responses to Hypertriglyceridemia and Bioactive Lipids. | Alberici LC et al. | β | 2022 | β |
| Non-alcoholic Fatty Liver Disease and Steatohepatitis: Risk Factors and Pathophysiology. | Akter S | β | 2022 | β |
| Recent advances in lean NAFLD. | Xu R et al. | β | 2022 | β |
| Role and Regulation of Wnt/Ξ²-Catenin in Hepatic Perivenous Zonation and Physiological Homeostasis. | Goel C et al. | β | 2022 | β |
| The p-STAT3/ANXA2 axis promotes caspase-1-mediated hepatocyte pyroptosis in non-alcoholic steatohepatitis. | Feng Y et al. | β | 2022 | β |
| Associations Among Methylene Tetrahydrofolate Reductase rs1801133 <i>C677T</i> Gene Variant, Food Groups, and Non-alcoholic Fatty Liver Disease Risk in the Chinese Population. | Hao X et al. | β | 2021 | β |
| Beverages and Non-alcoholic fatty liver disease (NAFLD): Think before you drink. | Chhimwal J et al. | β | 2021 | β |
| Chronic High Fat Diet Intake Impairs Hepatic Metabolic Parameters in Ovariectomized Sirt3 KO Mice. | PinteriΔ M et al. | β | 2021 | β |
| CYP2E1 in Alcoholic and Non-Alcoholic Liver Injury. Roles of ROS, Reactive Intermediates and Lipid Overload. | HarjumΓ€ki R et al. | β | 2021 | β |
| Excesive consumption of unsaturated fatty acids leads to oxidative and inflammatory instability in Wistar rats. | GrujiΔ-MilanoviΔ JD et al. | β | 2021 | β |
| <i>Lrp6</i> Genotype affects Individual Susceptibility to Nonalcoholic Fatty Liver Disease and Silibinin Therapeutic Response via Wnt/Ξ²-catenin-Cyp2e1 Signaling. | Chen LJ et al. | β | 2021 | β |
| Lipid based nanocarriers for effective drug delivery and treatment of diabetes associated liver fibrosis. | Salunkhe SA et al. | β | 2021 | β |
| Lipoic Acid Exacerbates Oxidative Stress and Lipid Accumulation in the Liver of Wistar Rats Fed a Hypercaloric Choline-Deficient Diet. | Kravchenko LV et al. | β | 2021 | β |
| MUTYH is associated with hepatocarcinogenesis in a non-alcoholic steatohepatitis mouse model. | Sakamoto H et al. | β | 2021 | β |
| Ovariectomy-Induced Hepatic Lipid and Cytochrome P450 Dysmetabolism Precedes Serum Dyslipidemia. | MalinskΓ‘ H et al. | β | 2021 | β |
| Pathophysiological mechanisms and clinical evidence of relationship between Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease. | Galiero R et al. | β | 2021 | β |
| Role of CC chemokine receptor 9 in the progression of murine and human non-alcoholic steatohepatitis. | Morikawa R et al. | β | 2021 | β |
| Role of chronic inflammation in the pathogenesis of nonalcoholic steatohepatitis: lessons from a unique mouse model using melanocortin receptor-deficient mice. | Itoh M et al. | β | 2021 | β |
| Role of mitochondria in liver metabolic health and diseases. | Morio B et al. | β | 2021 | β |
| Role of Neutrophils in the Pathogenesis of Nonalcoholic Steatohepatitis. | Hwang S et al. | β | 2021 | β |
| Targeting the eicosanoid pathway in hepatocellular carcinoma. | Razdan A et al. | β | 2021 | β |
| The Effectiveness of Dietary Byproduct Antioxidants on Induced CYP Genes Expression and Histological Alteration in Piglets Liver and Kidney Fed with Aflatoxin B1 and Ochratoxin A. | Popescu RG et al. | β | 2021 | β |
| The pivotal role of heme Oxygenase-1 in reversing the pathophysiology and systemic complications of NAFLD. | Sasson A et al. | β | 2021 | β |
| The role of SHP/REV-ERBΞ±/CYP4A axis in the pathogenesis of alcohol-associated liver disease. | Yang Z et al. | β | 2021 | β |
| Val-Val-Tyr-Pro protects against non-alcoholic steatohepatitis in mice by modulating the gut microbiota and gut-liver axis activation. | Xie X et al. | β | 2021 | β |
| Vitamin C Deficiency Inhibits Nonalcoholic Fatty Liver Disease Progression through Impaired de Novo Lipogenesis. | Lee SW et al. | β | 2021 | β |
| Acetyl-CoA carboxylase 1 and 2 inhibition ameliorates steatosis and hepatic fibrosis in a MC4R knockout murine model of nonalcoholic steatohepatitis. | Matsumoto M et al. | β | 2020 | β |
| An albino mouse model of nonalcoholic fatty liver disease induced using high-fat liquid "Lieber-DeCarli" diet: a preliminary investigation. | Ore A et al. | β | 2020 | β |
| Carbon tetrachloride (CCl<sub>4</sub>) accelerated development of non-alcoholic fatty liver disease (NAFLD)/steatohepatitis (NASH) in MS-NASH mice fed western diet supplemented with fructose (WDF). | Zhang G et al. | β | 2020 | β |
| CYP4A11 is involved in the development of nonalcoholic fatty liver disease via ROSβinduced lipid peroxidation and inflammation. | Gao H et al. | β | 2020 | β |
| Herb-drug interaction studies of herbs used in treatment of cardiovascular disorders-A narrative review of preclinical and clinical studies. | Shaikh AS et al. | β | 2020 | β |
| High-fat diet induces fibrosis in mice lacking CYP2A5 and PPARΞ±: a new model for steatohepatitis-associated fibrosis. | Chen X et al. | β | 2020 | β |
| History of Nonalcoholic Fatty Liver Disease. | Lonardo A et al. | β | 2020 | β |
| Honokiol Alleviates Methionine-Choline Deficient Diet-Induced Hepatic Steatosis and Oxidative Stress in C57BL/6 Mice by Regulating CFLAR-JNK Pathway. | Zhai T et al. | β | 2020 | β |
| Lemon Balm and Its Constituent, Rosmarinic Acid, Alleviate Liver Damage in an Animal Model of Nonalcoholic Steatohepatitis. | Kim M et al. | β | 2020 | β |
| MEHP/ethanol co-exposure favors the death of steatotic hepatocytes, possibly through CYP4A and ADH involvement. | TΓͺte A et al. | β | 2020 | β |
| Mitochondrial oxidative injury: a key player in nonalcoholic fatty liver disease. | Dornas W et al. | β | 2020 | β |
| Nonalcoholic Fatty Liver Disease in Adults: Current Concepts in Etiology, Outcomes, and Management. | Marjot T et al. | β | 2020 | β |
| Non-Alcoholic Steatohepatitis: A Review of Its Mechanism, Models and Medical Treatments. | Peng C et al. | β | 2020 | β |
| Pathophysiology of NAFLD and NASH in Experimental Models: The Role of Food Intake Regulating Peptides. | KoΕΓnkovΓ‘ L et al. | β | 2020 | β |
| PGC-1<i>Ξ±</i>, Inflammation, and Oxidative Stress: An Integrative View in Metabolism. | Rius-PΓ©rez S et al. | β | 2020 | β |
| Serum miR-379 expression is related to the development and progression of hypercholesterolemia in non-alcoholic fatty liver disease. | Okamoto K et al. | β | 2020 | β |
| Targeting ferroptosis alleviates methionine-choline deficient (MCD)-diet induced NASH by suppressing liver lipotoxicity. | Li X et al. | β | 2020 | β |
| The offspring from rats fed a fatty diet display impairments in the activation of liver peroxisome proliferator activated receptor alpha and features of fatty liver disease. | Heinecke F et al. | β | 2020 | β |
| Vitamin D receptor targets hepatocyte nuclear factor 4Ξ± and mediates protective effects of vitamin D in nonalcoholic fatty liver disease. | Zhang H et al. | β | 2020 | β |
| Why Hepatic CYP2E1-Elevation by Itself Is Insufficient for Inciting NAFLD/NASH: Inferences from Two Genetic Knockout Mouse Models. | Correia MA et al. | β | 2020 | β |
| Ξ²-Sitosterol attenuates liver injury in a rat model of chronic alcohol intake. | Chen Z et al. | β | 2020 | β |
| Administration of methyl palmitate prevents non-alcoholic steatohepatitis (NASH) by induction of PPAR-Ξ±. | Zhang L et al. | β | 2019 | β |
| Animal models of NAFLD from a hepatologist's point of view. | Jahn D et al. | β | 2019 | β |
| CYP2A6 is associated with obesity: studies in human samples and a high fat diet mouse model. | Wang K et al. | β | 2019 | β |
| Effects of duodenal-jejunal bypass surgery in ameliorating nonalcoholic steatohepatitis in diet-induced obese rats. | Yu HH et al. | β | 2019 | β |
| Fermented ginseng, GBCK25, ameliorates steatosis and inflammation in nonalcoholic steatohepatitis model. | Choi N et al. | β | 2019 | β |
| Immune-Deficient Pfp/Rag2<sup>-/-</sup> Mice Featured Higher Adipose Tissue Mass and Liver Lipid Accumulation with Growing Age than Wildtype C57BL/6N Mice. | Winkler S et al. | β | 2019 | β |
| In Utero Dexamethasone Exposure Exacerbates Hepatic Steatosis in Rats That Consume Fructose During Adulthood. | Payolla TB et al. | β | 2019 | β |
| Mitochondrial Dysfunction in the Transition from NASH to HCC. | LΓ©veillΓ© M et al. | β | 2019 | β |
| Oxidative Stress and Antioxidant Biomarkers in Clinical and Experimental Models of Non-Alcoholic Fatty Liver Disease. | Ore A et al. | β | 2019 | β |
| Past, present and future perspectives in nonalcoholic fatty liver disease. | Sanyal AJ | β | 2019 | β |
| Silibinin ameliorates hepatic lipid accumulation and oxidative stress in mice with non-alcoholic steatohepatitis by regulating CFLAR-JNK pathway. | Liu Y et al. | β | 2019 | β |
| Targeting CYP4A attenuates hepatic steatosis in a novel multicellular organotypic liver model. | Ryu JS et al. | β | 2019 | β |
| Vitamin D Deficiency Attenuates Acute Alcohol-Induced Hepatic Lipid Accumulation in Mice. | Hu CQ et al. | β | 2019 | β |
| 2,3,5,4'-tetrahydroxy-stilbene-2-O-Ξ²-D-glucoside attenuates methionine and choline-deficient diet-induced non-alcoholic fatty liver disease. | Han M et al. | β | 2018 | β |
| Alterations in the gene expression of drug and arachidonic acid-metabolizing Cyp450 in the livers of controlled and uncontrolled insulin-dependent diabetic mice. | Jarrar YB et al. | β | 2018 | β |
| Asking the Right Questions With Animal Models: Methionine- and Choline-Deficient Model in Predicting Adverse Drug Reactions in Human NASH. | Li H et al. | β | 2018 | β |
| Catalase and nonalcoholic fatty liver disease. | Shin SK et al. | β | 2018 | β |
| Dihydrocurcumin ameliorates the lipid accumulation, oxidative stress and insulin resistance in oleic acid-induced L02 and HepG2 cells. | Yu Q et al. | β | 2018 | β |
| Dual role of protein tyrosine phosphatase 1B in the progression and reversion of non-alcoholic steatohepatitis. | GonzΓ‘lez-RodrΓguez Γ et al. | β | 2018 | β |
| Effect of Phyllanthus emblica L. fruit on methionine and choline-deficiency diet-induced nonalcoholic steatohepatitis. | Tung YT et al. | β | 2018 | β |
| Effects of Honokiol on CYP450 Activity and Transporter mRNA Expression in Type 2 Diabetic Rats. | Wang J et al. | β | 2018 | β |
| Freshwater clam extract reduces liver injury by lowering cholesterol accumulation, improving dysregulated cholesterol synthesis and alleviating inflammation in high-fat, high-cholesterol and cholic acid diet-induced steatohepatitis in mice. | Yao HT et al. | β | 2018 | β |
| Glycine N-methyltransferase inhibits aristolochic acid nephropathy by increasing CYP3A44 and decreasing NQO1 expression in female mouse hepatocytes. | Chang MM et al. | β | 2018 | β |
| Hot water extract of turmeric (<i>Curcuma longa</i>) prevents non-alcoholic steatohepatitis in mice by inhibiting hepatic oxidative stress and inflammation. | Uchio R et al. | β | 2018 | β |
| Influence of gut microbiota on the development and progression of nonalcoholic steatohepatitis. | de Faria Ghetti F et al. | β | 2018 | β |
| Mitochondrial Dysfunction and Signaling in Chronic Liver Diseases. | Mansouri A et al. | β | 2018 | β |
| Mouse models of non-alcoholic steatohepatitis: A reflection on recent literature. | Haczeyni F et al. | β | 2018 | β |
| Novel non-alcoholic steatohepatitis model with histopathological and insulin-resistant features. | Owada Y et al. | β | 2018 | β |
| Pathogenesis of NASH: How Metabolic Complications of Overnutrition Favour Lipotoxicity and Pro-Inflammatory Fatty Liver Disease. | Farrell GC et al. | β | 2018 | β |
| Review article: drug-induced liver injury in the context of nonalcoholic fatty liver disease - a physiopathological and clinical integrated view. | Bessone F et al. | β | 2018 | β |
| The NOX1 isoform of NADPH oxidase is involved in dysfunction of liver sinusoids in nonalcoholic fatty liver disease. | Matsumoto M et al. | β | 2018 | β |
| Vitamin E as a Treatment for Nonalcoholic Fatty Liver Disease: Reality or Myth? | El Hadi H et al. | β | 2018 | β |
| Ablation of cytochrome P450 omega-hydroxylase 4A14 gene attenuates hepatic steatosis and fibrosis. | Zhang X et al. | β | 2017 | β |
| Administration of multipotent mesenchymal stromal cells restores liver regeneration and improves liver function in obese mice with hepatic steatosis after partial hepatectomy. | Ezquer F et al. | β | 2017 | β |
| Alleviative effect of ciliary neurotrophic factor analogue on high fat-induced hepatic steatosis is partially independent of the central regulation. | Cui MX et al. | β | 2017 | β |
| Branched-chain amino acids alleviate hepatic steatosis and liver injury in choline-deficient high-fat diet induced NASH mice. | Honda T et al. | β | 2017 | β |
| CD18 deficiency improves liver injury in the MCD model of steatohepatitis. | Pierce AA et al. | β | 2017 | β |
| Changes in drug transport and metabolism and their clinical implications in non-alcoholic fatty liver disease. | Dietrich CG et al. | β | 2017 | β |
| Chicoric acid attenuate a nonalcoholic steatohepatitis by inhibiting key regulators of lipid metabolism, fibrosis, oxidation, and inflammation in mice with methionine and choline deficiency. | Kim M et al. | β | 2017 | β |
| Comparative study of fatty liver induced by methionine and choline-deficiency in C57BL/6N mice originating from three different sources. | Kim SH et al. | β | 2017 | β |
| Connexin32 deficiency is associated with liver injury, inflammation and oxidative stress in experimental non-alcoholic steatohepatitis. | Tiburcio TC et al. | β | 2017 | β |
| Genetic Nrf2 Overactivation Inhibits the Deleterious Effects Induced by Hepatocyte-Specific c-met Deletion during the Progression of NASH. | Ramadori P et al. | β | 2017 | β |
| Janus Kinase 2 (JAK2) Dissociates Hepatosteatosis from Hepatocellular Carcinoma in Mice. | Shi SY et al. | β | 2017 | β |
| Methyl donor deficient diets cause distinct alterations in lipid metabolism but are poorly representative of human NAFLD. | Lyall MJ et al. | β | 2017 | β |
| Neuronal Cell Death and Degeneration through Increased Nitroxidative Stress and Tau Phosphorylation in HIV-1 Transgenic Rats. | Cho YE et al. | β | 2017 | β |
| NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice. | Mridha AR et al. | β | 2017 | β |
| Placental extract ameliorates non-alcoholic steatohepatitis (NASH) by exerting protective effects on endothelial cells. | Yamauchi A et al. | β | 2017 | β |
| Role of ADAMTS13 in diet-induced liver steatosis. | Geys L et al. | β | 2017 | β |
| Role of CYP2E1 in Mitochondrial Dysfunction and Hepatic Injury by Alcohol and Non-Alcoholic Substances. | Abdelmegeed MA et al. | β | 2017 | β |
| Steatosis and NASH in type 2 diabetes. | Hu M et al. | β | 2017 | β |
| The Contribution of Singlet Oxygen to Insulin Resistance. | Onyango AN | β | 2017 | β |
| The TIR/BB-loop mimetic AS-1 prevents non-alcoholic steatohepatitis and hepatic insulin resistance by inhibiting NLRP3-ASC inflammasome activation. | Wang X et al. | β | 2017 | β |
| Toxicological Implications of Mitochondrial Localization of CYP2E1. | Hartman JH et al. | β | 2017 | β |
| A High-Fat, High-Fructose Diet Induces Antioxidant Imbalance and Increases the Risk and Progression of Nonalcoholic Fatty Liver Disease in Mice. | Jarukamjorn K et al. | β | 2016 | β |
| Animal Models of Nonalcoholic Steatohepatitis: Eat, Delete, and Inflame. | Ibrahim SH et al. | β | 2016 | β |
| A Series of microRNA in the Chromosome 14q32.2 Maternally Imprinted Region Related to Progression of Non-Alcoholic Fatty Liver Disease in a Mouse Model. | Okamoto K et al. | β | 2016 | β |
| Being right on Q: shaping eukaryotic evolution. | Speijer D | β | 2016 | β |
| Berberine prevents progression from hepatic steatosis to steatohepatitis and fibrosis by reducing endoplasmic reticulum stress. | Zhang Z et al. | β | 2016 | β |
| CHIP(-/-)-Mouse Liver: Adiponectin-AMPK-FOXO-Activation Overrides CYP2E1-Elicited JNK1-Activation, Delaying Onset of NASH: Therapeutic Implications. | Kim SM et al. | β | 2016 | β |
| C-X-C motif chemokine 10 in non-alcoholic steatohepatitis: role as a pro-inflammatory factor and clinical implication. | Xu Z et al. | β | 2016 | β |
| Effects of Nonpurified and Choline Supplemented or Nonsupplemented Purified Diets on Hepatic Steatosis and Methionine Metabolism in C3H Mice. | Syed R et al. | β | 2016 | β |
| Hepatic FTO expression is increased in NASH and its silencing attenuates palmitic acid-induced lipotoxicity. | Lim A et al. | β | 2016 | β |
| Hepatoprotective Effect and Synergism of Bisdemethoycurcumin against MCD Diet-Induced Nonalcoholic Fatty Liver Disease in Mice. | Kim SB et al. | β | 2016 | β |
| Isocaloric manipulation of macronutrients within a high-carbohydrate/moderate-fat diet induces unique effects on hepatic lipogenesis, steatosis and liver injury. | Pierce AA et al. | β | 2016 | β |
| Obese Mice Fed a Diet Supplemented with Enzyme-Treated Wheat Bran Display Marked Shifts in the Liver Metabolome Concurrent with Altered Gut Bacteria. | Kieffer DA et al. | β | 2016 | β |
| Pathophysiology and Mechanisms of Nonalcoholic Fatty Liver Disease. | Haas JT et al. | β | 2016 | β |
| Regulated Inflammation and Lipid Metabolism in Colon mRNA Expressions of Obese Germfree Mice Responding to <i>Enterobacter cloacae</i> B29 Combined with the High Fat Diet. | Yan H et al. | β | 2016 | β |
| Rifampicin-Induced Hepatic Lipid Accumulation: Association with Up-Regulation of Peroxisome Proliferator-Activated Receptor Ξ³ in Mouse Liver. | Huang JH et al. | β | 2016 | β |
| Controlled-release mitochondrial protonophore reverses diabetes and steatohepatitis in rats. | Perry RJ et al. | β | 2015 | β |
| Dietary Supplementation of Genistein Alleviates Liver Inflammation and Fibrosis Mediated by a Methionine-Choline-Deficient Diet in db/db Mice. | Yoo NY et al. | β | 2015 | β |
| Green Tea Lowers Hepatic COX-2 and Prostaglandin E2 in Rats with Dietary Fat-Induced Nonalcoholic Steatohepatitis. | Chung MY et al. | β | 2015 | β |
| Gut microbiome and nonalcoholic fatty liver diseases. | Zhu L et al. | β | 2015 | β |
| Houttuynia cordata alleviates high-fat diet-induced non-alcoholic fatty liver in experimental rats. | Kang H et al. | β | 2015 | β |
| Modulation of hepatic lipid metabolism by olive oil and its phenols in nonalcoholic fatty liver disease. | Priore P et al. | β | 2015 | β |
| Novel insights into the mechanisms whereby isoflavones protect against fatty liver disease. | Qiu LX et al. | β | 2015 | β |
| Proteomic analysis of mice fed methionine and choline deficient diet reveals marker proteins associated with steatohepatitis. | Lee SJ et al. | β | 2015 | β |
| Pulsed Azidohomoalanine Labeling in Mammals (PALM) Detects Changes in Liver-Specific LKB1 Knockout Mice. | McClatchy DB et al. | β | 2015 | β |
| Quercetin ameliorates dysregulation of lipid metabolism genes via the PI3K/AKT pathway in a diet-induced mouse model of nonalcoholic fatty liver disease. | Pisonero-Vaquero S et al. | β | 2015 | β |
| Role of the Red Ginseng in Defense against the Environmental Heat Stress in Sprague Dawley Rats. | Kim KJ et al. | β | 2015 | β |
| Strategies, models and biomarkers in experimental non-alcoholic fatty liver disease research. | Willebrords J et al. | β | 2015 | β |
| The xanthine oxidase inhibitor febuxostat suppresses development of nonalcoholic steatohepatitis in a rodent model. | Nakatsu Y et al. | β | 2015 | β |
| Translational Implications of the Alcohol-Metabolizing Enzymes, Including Cytochrome P450-2E1, in Alcoholic and Nonalcoholic Liver Disease. | Song BJ et al. | β | 2015 | β |
| Use of farnesoid X receptor agonists to treat nonalcoholic fatty liver disease. | Sanyal AJ | β | 2015 | β |
| Acetaminophen-induced liver injury in obesity and nonalcoholic fatty liver disease. | Michaut A et al. | β | 2014 | β |
| Binge alcohol consumption aggravates oxidative stress and promotes pathogenesis of NASH from obesity-induced simple steatosis. | Minato T et al. | β | 2014 | β |
| Bofutsushosan, a Japanese herbal (Kampo) medicine, attenuates progression of nonalcoholic steatohepatitis in mice. | Ono M et al. | β | 2014 | β |
| CXCL10 plays a key role as an inflammatory mediator and a non-invasive biomarker of non-alcoholic steatohepatitis. | Zhang X et al. | β | 2014 | β |
| Development of hepatocellular carcinoma in a murine model of nonalcoholic steatohepatitis induced by use of a high-fat/fructose diet and sedentary lifestyle. | Dowman JK et al. | β | 2014 | β |
| Dietary glycotoxins exacerbate progression of experimental fatty liver disease. | Leung C et al. | β | 2014 | β |
| Effect of Trifolium pratense extract on methionine-choline-deficient diet-induced steatohepatitis in C57BL/6 mice. | Chen T et al. | β | 2014 | β |
| Free cholesterol accumulation in hepatic stellate cells: mechanism of liver fibrosis aggravation in nonalcoholic steatohepatitis in mice. | Tomita K et al. | β | 2014 | β |
| Functional roles of protein nitration in acute and chronic liver diseases. | Abdelmegeed MA et al. | β | 2014 | β |
| Hepatoprotective and antioxidant activities of extracts from Salvia-Nelumbinis naturalis against nonalcoholic steatohepatitis induced by methionine- and choline-deficient diet in mice. | Liu Y et al. | β | 2014 | β |
| How the mitochondrion was shaped by radical differences in substrates: what carnitine shuttles and uncoupling tell us about mitochondrial evolution in response to ROS. | Speijer D | β | 2014 | β |
| Influence of fat/carbohydrate ratio on progression of fatty liver disease and on development of osteopenia in male rats fed alcohol via total enteral nutrition (TEN). | Ronis MJ et al. | β | 2014 | β |
| Inhibition of CYP4A reduces hepatic endoplasmic reticulum stress and features of diabetes in mice. | Park EC et al. | β | 2014 | β |
| Inhibitory effects of Japanese herbal medicines sho-saiko-to and juzen-taiho-to on nonalcoholic steatohepatitis in mice. | Takahashi Y et al. | β | 2014 | β |
| Leukocyte activity in patients with ST-segment elevation acute myocardial infarction treated with anakinra. | Sonnino C et al. | β | 2014 | β |
| Lipotoxic effect of p21 on free fatty acid-induced steatosis in L02 cells. | Wang JW et al. | β | 2014 | β |
| Liver proteomic response to hypertriglyceridemia in human-apolipoprotein C-III transgenic mice at cellular and mitochondrial compartment levels. | Ehx G et al. | β | 2014 | β |
| Maternal choline modifies fetal liver copper, gene expression, DNA methylation, and neonatal growth in the tx-j mouse model of Wilson disease. | Medici V et al. | β | 2014 | β |
| Modeling human nonalcoholic steatohepatitis-associated changes in drug transporter expression using experimental rodent models. | Canet MJ et al. | β | 2014 | β |
| Non-alcoholic fatty liver disease: spectral patterns observed from an in vivo phosphorus magnetic resonance spectroscopy study. | Abrigo JM et al. | β | 2014 | β |
| Reactive oxygen and nitrogen species in steatotic hepatocytes: a molecular perspective on the pathophysiology of ischemia-reperfusion injury in the fatty liver. | Reiniers MJ et al. | β | 2014 | β |
| Role of adipose tissue in methionine-choline-deficient model of non-alcoholic steatohepatitis (NASH). | Jha P et al. | β | 2014 | β |
| Sitagliptin attenuates methionine/choline-deficient diet-induced steatohepatitis. | Jung YA et al. | β | 2014 | β |
| Standardized Salvia miltiorrhiza extract suppresses hepatic stellate cell activation and attenuates steatohepatitis induced by a methionine-choline deficient diet in mice. | Lee HS et al. | β | 2014 | β |
| Systems level metabolic phenotype of methotrexate administration in the context of non-alcoholic steatohepatitis in the rat. | Kyriakides M et al. | β | 2014 | β |
| The transrepressive activity of peroxisome proliferator-activated receptor alpha is necessary and sufficient to prevent liver fibrosis in mice. | Pawlak M et al. | β | 2014 | β |
| A 360-degree overview of paediatric NAFLD: recent insights. | Nobili V et al. | β | 2013 | β |
| A high-fat diet and multiple administration of carbon tetrachloride induces liver injury and pathological features associated with non-alcoholic steatohepatitis in mice. | Kubota N et al. | β | 2013 | β |
| Aldose reductase is involved in the development of murine diet-induced nonalcoholic steatohepatitis. | Qiu L et al. | β | 2013 | β |
| Alterations in the redox state and liver damage: hints from the EASL Basic School of Hepatology. | Tell G et al. | β | 2013 | β |
| Changes in the hepatic mitochondrial and membrane proteome in mice fed a non-alcoholic steatohepatitis inducing diet. | Thomas A et al. | β | 2013 | β |
| Chunggan extract (CGX), methionine-and choline-deficient (MCD) diet-induced hepatosteatosis and oxidative stress in C57BL/6 mice. | Park HJ et al. | β | 2013 | β |
| Curcumin and liver disease. | Vera-Ramirez L et al. | β | 2013 | β |
| CYP2E1 and oxidant stress in alcoholic and non-alcoholic fatty liver disease. | Leung TM et al. | β | 2013 | β |
| Cytochrome P4502E1 inhibitor, chlormethiazole, decreases lipopolysaccharide-induced inflammation in rat Kupffer cells with ethanol treatment. | Ye Q et al. | β | 2013 | β |
| Cytochrome P450 2E1: its clinical aspects and a brief perspective on the current research scenario. | Dey A | β | 2013 | β |
| Effect of tomato extract supplementation against high-fat diet-induced hepatic lesions. | Melendez-Martinez AJ et al. | β | 2013 | β |
| Eicosanoids in metabolic syndrome. | Hardwick JP et al. | β | 2013 | β |
| Expression of cytochrome P450 2A5 in a C57BL/6J mouse model of nonalcoholic fatty liver disease. | Li R et al. | β | 2013 | β |
| Hair selenium levels in hepatic steatosis patients. | Pan D et al. | β | 2013 | β |
| Hepatocyte caspase-8 is an essential modulator of steatohepatitis in rodents. | Hatting M et al. | β | 2013 | β |
| Impact of PPAR-Ξ± induction on glucose homoeostasis in alcohol-fed mice. | Lebrun V et al. | β | 2013 | β |
| Increased nitroxidative stress promotes mitochondrial dysfunction in alcoholic and nonalcoholic fatty liver disease. | Song BJ et al. | β | 2013 | β |
| In vitro and in vivo models of non-alcoholic fatty liver disease (NAFLD). | Kanuri G et al. | β | 2013 | β |
| Lipotoxicity in the liver. | ZΓ‘mbΓ³ V et al. | β | 2013 | β |
| [Mechanism of hepatoprotective action of methionine and composition "Metovitan" against a background of antituberculosis drug administration to rats]. | Anisimova SI et al. | β | 2013 | β |
| Mediation of in vitro cytochrome p450 activity by common pharmaceutical excipients. | Martin P et al. | β | 2013 | β |
| Molecular Interactions between NAFLD and Xenobiotic Metabolism. | Naik A et al. | β | 2013 | β |
| Non-alcoholic steatohepatitis and hepatocellular carcinoma: implications for lycopene intervention. | Ip BC et al. | β | 2013 | β |
| Oils rich in Ξ±-linolenic acid independently protect against characteristics of fatty liver disease in the Ξ6-desaturase null mouse. | Monteiro J et al. | β | 2013 | β |
| Pathophysiology of NASH: perspectives for a targeted treatment. | Marra F et al. | β | 2013 | β |
| Patients with Nonalcoholic Fatty Liver Disease (NAFLD) have Higher Oxidative Stress in Comparison to Chronic Viral Hepatitis. | Kumar A et al. | β | 2013 | β |
| Rapid chromatographic method to decipher distinct alterations in lipid classes in NAFLD/NASH. | Laggai S et al. | β | 2013 | β |
| Relevance of CYP2E1 to non-alcoholic fatty liver disease. | Daly AK | β | 2013 | β |
| Sex steroid hormones regulate constitutive expression of Cyp2e1 in female mouse liver. | Konstandi M et al. | β | 2013 | β |
| Triterpenoid-rich fraction from Ilex hainanensis Merr. attenuates non-alcoholic fatty liver disease induced by high fat diet in rats. | Cui WX et al. | β | 2013 | β |
| Validated liquid chromatography-tandem mass spectrometry method for determination of totally nine probe metabolites of cytochrome P450 enzymes and UDP-glucuronosyltransferases. | Lee JT et al. | β | 2013 | β |
| Zidovudine (AZT) and hepatic lipid accumulation: implication of inflammation, oxidative and endoplasmic reticulum stress mediators. | Banerjee A et al. | β | 2013 | β |
| Alpha-lipoic acid attenuates methionine choline deficient diet-induced steatohepatitis in C57BL/6 mice. | Min AK et al. | β | 2012 | β |
| Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. | Takahashi Y et al. | β | 2012 | β |
| An overview of the evidence and mechanisms of herb-drug interactions. | Fasinu PS et al. | β | 2012 | β |
| Anti-oxidative and anti-inflammatory effects of spirulina on rat model of non-alcoholic steatohepatitis. | Pak W et al. | β | 2012 | β |
| Carnosic acid (CA) prevents lipid accumulation in hepatocytes through the EGFR/MAPK pathway. | Wang T et al. | β | 2012 | β |
| Central role of mitochondria in drug-induced liver injury. | Pessayre D et al. | β | 2012 | β |
| Choline deprivation: an overview of the major hepatic metabolic response pathways. | Al-Humadi H et al. | β | 2012 | β |
| Effects of dietary inulin, statin, and their co-treatment on hyperlipidemia, hepatic steatosis and changes in drug-metabolizing enzymes in rats fed a high-fat and high-sucrose diet. | Sugatani J et al. | β | 2012 | β |
| Ethanol-induced oxidative stress via the CYP2E1 pathway disrupts adiponectin secretion from adipocytes. | Tang H et al. | β | 2012 | β |
| Group IVA phospholipase A2 participates in the progression of hepatic fibrosis. | Ishihara K et al. | β | 2012 | β |
| Hepatic endothelin-1 and endocannabinoids-dependent effects of hyperleptinemia in nonalcoholic steatohepatitis-cirrhotic rats. | Yang YY et al. | β | 2012 | β |
| Hepatocyte growth factor overexpression ameliorates liver inflammation and fibrosis in a mouse model of nonalcoholic steatohepatitis. | Tojima H et al. | β | 2012 | β |
| Lack of CC chemokine ligand 2 differentially affects inflammation and fibrosis according to the genetic background in a murine model of steatohepatitis. | Galastri S et al. | β | 2012 | β |
| Molecular alterations in hepatocarcinogenesis induced by dietary methyl deficiency. | Pogribny IP et al. | β | 2012 | β |
| NASH is an Inflammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications. | Farrell GC et al. | β | 2012 | β |
| Neutrophil-derived myeloperoxidase aggravates non-alcoholic steatohepatitis in low-density lipoprotein receptor-deficient mice. | Rensen SS et al. | β | 2012 | β |
| p53/p66Shc-mediated signaling contributes to the progression of non-alcoholic steatohepatitis in humans and mice. | Tomita K et al. | β | 2012 | β |
| Protective effects of tiopronin against high fat diet-induced non-alcoholic steatohepatitis in rats. | Wang JQ et al. | β | 2012 | β |
| Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. | Rolo AP et al. | β | 2012 | β |
| Silymarin suppresses hepatic stellate cell activation in a dietary rat model of non-alcoholic steatohepatitis: analysis of isolated hepatic stellate cells. | Kim M et al. | β | 2012 | β |
| Ursodeoxycholyl lysophosphatidylethanolamide improves steatosis and inflammation in murine models of nonalcoholic fatty liver disease. | Pathil A et al. | β | 2012 | β |
| Adiponectin, a key adipokine in obesity related liver diseases. | Buechler C et al. | β | 2011 | β |
| Alcoholic liver disease and exacerbation by malnutrition and infections: what animal models are currently available? | Bergheim I et al. | β | 2011 | β |
| A mouse model for nonalcoholic steatohepatitis. | Sundaresan S et al. | β | 2011 | β |
| Animal models for the study of hepatic fibrosis. | Starkel P et al. | β | 2011 | β |
| Animal models of nonalcoholic fatty liver disease. | Hebbard L et al. | β | 2011 | β |
| Assessment of subclinical, toxicant-induced hepatic gene expression profiles after low-dose, short-term exposures in mice. | Zheng JL et al. | β | 2011 | β |
| Association of polymorphisms in glutamate-cysteine ligase catalytic subunit and microsomal triglyceride transfer protein genes with nonalcoholic fatty liver disease. | Hashemi M et al. | β | 2011 | β |
| Black tea prevents high fat diet-induced non-alcoholic steatohepatitis. | Karmakar S et al. | β | 2011 | β |
| Constitutive active/androstane receptor promotes hepatocarcinogenesis in a mouse model of non-alcoholic steatohepatitis. | Takizawa D et al. | β | 2011 | β |
| Cytochrome P450 2E1 and hyperglycemia-induced liver injury. | Dey A et al. | β | 2011 | β |
| Discovering networks of perturbed biological processes in hepatocyte cultures. | Lasher CD et al. | β | 2011 | β |
| Drug-induced toxicity on mitochondria and lipid metabolism: mechanistic diversity and deleterious consequences for the liver. | Begriche K et al. | β | 2011 | β |
| Drug metabolism alterations in nonalcoholic fatty liver disease. | Merrell MD et al. | β | 2011 | β |
| Enhanced expression of pro-inflammatory mediators and liver X-receptor-regulated lipogenic genes in non-alcoholic fatty liver disease and hepatitis C. | Lima-Cabello E et al. | β | 2011 | β |
| Fibrogenesis in nonalcoholic steatohepatitis. | De Minicis S et al. | β | 2011 | β |
| Fibrosis in alcoholic and nonalcoholic steatohepatitis. | Bataller R et al. | β | 2011 | β |
| Hepatic lipid peroxidation and cytochrome P-450 2E1 in pediatric nonalcoholic fatty liver disease and its subtypes. | Bell LN et al. | β | 2011 | β |
| Hepatoprotective effects of geniposide in a rat model of nonalcoholic steatohepatitis. | Ma T et al. | β | 2011 | β |
| Kupffer cell depletion prevents but has no therapeutic effect on metabolic and inflammatory changes induced by a high-fat diet. | Lanthier N et al. | β | 2011 | β |
| Mechanisms linking nonalcoholic fatty liver disease with coronary artery disease. | Nseir W et al. | β | 2011 | β |
| Metabolic pathways promoting intrahepatic fatty acid accumulation in methionine and choline deficiency: implications for the pathogenesis of steatohepatitis. | Macfarlane DP et al. | β | 2011 | β |
| Methionine- and choline-deficient diet induces hepatic changes characteristic of non-alcoholic steatohepatitis. | Marcolin E et al. | β | 2011 | β |
| Mitochondrial energy metabolism and redox responses to hypertriglyceridemia. | Alberici LC et al. | β | 2011 | β |
| New insights from rodent models of fatty liver disease. | Maher JJ | β | 2011 | β |
| Obesity, diabetes mellitus, and liver fibrosis. | Chiang DJ et al. | β | 2011 | β |
| PPARalpha expression protects male mice from high fat-induced nonalcoholic fatty liver. | Abdelmegeed MA et al. | β | 2011 | β |
| Redox balance in the pathogenesis of nonalcoholic fatty liver disease: mechanisms and therapeutic opportunities. | Gambino R et al. | β | 2011 | β |
| The role of oxidative stress in non-alcoholic steatohepatitis. | Koek GH et al. | β | 2011 | β |
| Transforming growth factor-Ξ± attenuates hepatic fibrosis: possible involvement of matrix metalloproteinase-1. | Ohyama T et al. | β | 2011 | β |
| Bariatric surgery-induced weight loss reduces hepatic lipid peroxidation levels and affects hepatic cytochrome P-450 protein content. | Bell LN et al. | β | 2010 | β |
| Bimodal targeting of microsomal cytochrome P450s to mitochondria: implications in drug metabolism and toxicity. | Sangar MC et al. | β | 2010 | β |
| Blockade of interleukin-6 signaling enhances hepatic steatosis but improves liver injury in methionine choline-deficient diet-fed mice. | Yamaguchi K et al. | β | 2010 | β |
| Curcumin limits the fibrogenic evolution of experimental steatohepatitis. | Vizzutti F et al. | β | 2010 | β |
| Cyclosporine-induced changes in drug metabolizing enzymes in hyperlipemic rabbit kidneys could explain its toxicity. | Elbarbry F et al. | β | 2010 | β |
| Cyp4a14 overexpression induced by hyperoxia in female CBA mice as a possible contributor of increased resistance to oxidative stress. | Sobocanec S et al. | β | 2010 | β |
| Deletion of nuclear factor-E2-related factor-2 leads to rapid onset and progression of nutritional steatohepatitis in mice. | Sugimoto H et al. | β | 2010 | β |
| Dietary fructose exacerbates hepatocellular injury when incorporated into a methionine-choline-deficient diet. | Pickens MK et al. | β | 2010 | β |
| Electron microscopic findings in non-alcoholic fatty liver disease: is there a difference between hepatosteatosis and steatohepatitis? | Ahishali E et al. | β | 2010 | β |
| Enhanced expression of Nrf2 in mice attenuates the fatty liver produced by a methionine- and choline-deficient diet. | Zhang YK et al. | β | 2010 | β |
| Experimental induction of steatosis in different tissues after the ingestion of a carbohydrate-rich diet: effect on the liver, on the heart and on indicators of oxidation. | Haubert NJ et al. | β | 2010 | β |
| Fatty liver and fibrosis in glycine N-methyltransferase knockout mice is prevented by nicotinamide. | Varela-Rey M et al. | β | 2010 | β |
| From the metabolic syndrome to NAFLD or vice versa? | Vanni E et al. | β | 2010 | β |
| Glucagon regulates intracellular distribution of adipose differentiation-related protein during triacylglycerol accumulation in the liver. | Takahashi K et al. | β | 2010 | β |
| Hepatoprotective effects of S-adenosyl-L-methionine against alcohol- and cytochrome P450 2E1-induced liver injury. | Cederbaum AI | β | 2010 | β |
| High-fructose, medium chain trans fat diet induces liver fibrosis and elevates plasma coenzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis. | Kohli R et al. | β | 2010 | β |
| Identification of a novel biomarker for oxidative stress induced by hydrogen peroxide in primary human hepatocytes using the 2-nitrobenzenesulfenyl chloride isotope labeling method. | Takami Y et al. | β | 2010 | β |
| Insulin- and leptin-regulated fatty acid uptake plays a key causal role in hepatic steatosis in mice with intact leptin signaling but not in ob/ob or db/db mice. | Ge F et al. | β | 2010 | β |
| JNK regulation of hepatic manifestations of the metabolic syndrome. | Czaja MJ | β | 2010 | β |
| Kupffer cell activation is a causal factor for hepatic insulin resistance. | Lanthier N et al. | β | 2010 | β |
| Liver-specific beta-catenin knockout mice exhibit defective bile acid and cholesterol homeostasis and increased susceptibility to diet-induced steatohepatitis. | Behari J et al. | β | 2010 | β |
| Loss of Nrf2 markedly exacerbates nonalcoholic steatohepatitis. | Chowdhry S et al. | β | 2010 | β |
| Macroautophagy and chaperone-mediated autophagy are required for hepatocyte resistance to oxidant stress. | Wang Y et al. | β | 2010 | β |
| Molecular basis for a functional role of cytochrome P450 2E1 in non-alcoholic steatohepatitis. | Wu CW et al. | β | 2010 | β |
| Nutritional status affects fluvastatin-induced hepatotoxicity and myopathy in rats. | Sugatani J et al. | β | 2010 | β |
| [Obesity and liver disease]. | Miquilena Colina ME et al. | β | 2010 | β |
| Oral N-acetylcysteine rescues lethality of hepatocyte-specific Gclc-knockout mice, providing a model for hepatic cirrhosis. | Chen Y et al. | β | 2010 | β |
| Oxidative stress and antioxidants in hepatic pathogenesis. | Ha HL et al. | β | 2010 | β |
| Oxidative stress induced by high-glucose diet in liver of C57BL/6J mice and its underlying mechanism. | Du D et al. | β | 2010 | β |
| PKC{delta} is activated in a dietary model of steatohepatitis and regulates endoplasmic reticulum stress and cell death. | Greene MW et al. | β | 2010 | β |
| The importance of fatty liver disease in clinical practice. | Cobbold JF et al. | β | 2010 | β |
| The latest idea in NAFLD/NASH pathogenesis. | Ono M et al. | β | 2010 | β |
| The role of ethanol metabolism in development of alcoholic steatohepatitis in the rat. | Ronis MJ et al. | β | 2010 | β |
| The vitamin E reduces liver lipoperoxidation and fibrosis in a model of nonalcoholic steatohepatitis. | Zamin I et al. | β | 2010 | β |
| Treatment with omega-3 fatty acids but not exendin-4 improves hepatic steatosis. | Bulchandani DG et al. | β | 2010 | β |
| A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: A randomized placebo-controlled trial. | Nelson A et al. | β | 2009 | β |
| Autophagy regulates lipid metabolism. | Singh R et al. | β | 2009 | β |
| Chronic oxidative stress sensitizes hepatocytes to death from 4-hydroxynonenal by JNK/c-Jun overactivation. | Singh R et al. | β | 2009 | β |
| c-Jun N-terminal kinase-1 from hematopoietic cells mediates progression from hepatic steatosis to steatohepatitis and fibrosis in mice. | Kodama Y et al. | β | 2009 | β |
| Dietary sucrose is essential to the development of liver injury in the methionine-choline-deficient model of steatohepatitis. | Pickens MK et al. | β | 2009 | β |
| Diet-induced obesity is associated with hyperleptinemia, hyperinsulinemia, hepatic steatosis, and glomerulopathy in C57Bl/6J mice. | Hoffler U et al. | β | 2009 | β |
| Differential induction of ethanol-metabolizing CYP2E1 and nicotine-metabolizing CYP2B1/2 in rat liver by chronic nicotine treatment and voluntary ethanol intake. | Yue J et al. | β | 2009 | β |
| Effects of Oxidized Frying Oil on Proteins Related to alpha-Tocopherol Metabolism in Rat Liver. | Huang WC et al. | β | 2009 | β |
| Ethanol-induced cytochrome P4502E1 causes carcinogenic etheno-DNA lesions in alcoholic liver disease. | Wang Y et al. | β | 2009 | β |
| Genetic polymorphism of metabolic enzymes P450 (CYP) as a susceptibility factor for drug response, toxicity, and cancer risk. | Bozina N et al. | β | 2009 | β |
| IL-6 deficiency attenuates murine diet-induced non-alcoholic steatohepatitis. | Mas E et al. | β | 2009 | β |
| Increased hepatic expression is a major determinant of serum alanine aminotransferase elevation in mice with nonalcoholic steatohepatitis. | Liu R et al. | β | 2009 | β |
| In vivo assessment of hepatic triglycerides in murine non-alcoholic fatty liver disease using magnetic resonance spectroscopy. | Corbin IR et al. | β | 2009 | β |
| Isolation stress for 30 days alters hepatic gene expression profiles, especially with reference to lipid metabolism in mice. | Motoyama K et al. | β | 2009 | β |
| Melatonin ameliorates methionine- and choline-deficient diet-induced nonalcoholic steatohepatitis in rats. | Tahan V et al. | β | 2009 | β |
| Mitochondrial ATP-sensitive K(+) channels as redox signals to liver mitochondria in response to hypertriglyceridemia. | Alberici LC et al. | β | 2009 | β |
| [Model of experimental nonalcoholic steatohepatitis from use of methionine and choline deficient diet]. | Zamin I et al. | β | 2009 | β |
| Modern strategies to identify new molecular targets for the treatment of liver diseases: The promising role of Proteomics and Redox Proteomics investigations. | Scaloni A et al. | β | 2009 | β |
| Molecular mechanisms involved in NAFLD progression. | Malaguarnera M et al. | β | 2009 | β |
| Molecular mechanisms of alcoholic fatty liver. | Purohit V et al. | β | 2009 | β |
| Nutritional model of steatohepatitis and metabolic syndrome in the Ossabaw miniature swine. | Lee L et al. | β | 2009 | β |
| Overview: Liver disease and transplantation. | Powell LW | β | 2009 | β |
| PPAR/RXR Regulation of Fatty Acid Metabolism and Fatty Acid omega-Hydroxylase (CYP4) Isozymes: Implications for Prevention of Lipotoxicity in Fatty Liver Disease. | Hardwick JP et al. | β | 2009 | β |
| Role of free radicals in liver diseases. | Muriel P | β | 2009 | β |
| Role of hepatic iron in non-alcoholic steatohepatitis. | Sumida Y et al. | β | 2009 | β |
| Role of oxidative stress in alcohol-induced liver injury. | Cederbaum AI et al. | β | 2009 | β |
| Role of peroxisome proliferator-activated receptor-alpha in fasting-mediated oxidative stress. | Abdelmegeed MA et al. | β | 2009 | β |
| Rosiglitazone prevents nutritional fibrosis and steatohepatitis in mice. | Nan YM et al. | β | 2009 | β |
| Similarities and differences in the pathogenesis of alcoholic and nonalcoholic steatohepatitis. | Syn WK et al. | β | 2009 | β |
| The liver and the waistline: Fifty years of growth. | Farrell GC | β | 2009 | β |
| Variants in the UGT1A1 gene and the risk of pediatric nonalcoholic fatty liver disease. | Lin YC et al. | β | 2009 | β |
| Activation of peroxisome proliferator-activated receptor alpha by dietary fish oil attenuates steatosis, but does not prevent experimental steatohepatitis because of hepatic lipoperoxide accumulation. | Larter CZ et al. | β | 2008 | β |
| Adipocytokines and liver disease. | Kamada Y et al. | β | 2008 | β |
| Altered expression patterns of lipid metabolism genes in an animal model of HCV core-related, nonobese, modest hepatic steatosis. | Chang ML et al. | β | 2008 | β |
| A new model for nonalcoholic steatohepatitis in the rat utilizing total enteral nutrition to overfeed a high-polyunsaturated fat diet. | Baumgardner JN et al. | β | 2008 | β |
| Animal models of NASH: getting both pathology and metabolic context right. | Larter CZ et al. | β | 2008 | β |
| CYP2E1 and oxidative liver injury by alcohol. | Lu Y et al. | β | 2008 | β |
| Cytochrome P450 2E1 contributes to ethanol-induced fatty liver in mice. | Lu Y et al. | β | 2008 | β |
| Cytochrome P450 omega hydroxylase (CYP4) function in fatty acid metabolism and metabolic diseases. | Hardwick JP | β | 2008 | β |
| Differential alterations in mitochondrial function induced by a choline-deficient diet: understanding fatty liver disease progression. | Teodoro JS et al. | β | 2008 | β |
| Disease-specific mechanisms of fibrosis: hepatitis C virus and nonalcoholic steatohepatitis. | van der Poorten D et al. | β | 2008 | β |
| Expression of hepatic UDP-glucuronosyltransferase 1A1 and 1A6 correlated with increased expression of the nuclear constitutive androstane receptor and peroxisome proliferator-activated receptor alpha in male rats fed a high-fat and high-sucrose diet. | Osabe M et al. | β | 2008 | β |
| Hepatic AdipoR2 signaling plays a protective role against progression of nonalcoholic steatohepatitis in mice. | Tomita K et al. | β | 2008 | β |
| Hepatic microcirculation in fatty liver disease. | Farrell GC et al. | β | 2008 | β |
| Interstrain differences in susceptibility to non-alcoholic steatohepatitis. | Yamazaki Y et al. | β | 2008 | β |
| MCD-induced steatohepatitis is associated with hepatic adiponectin resistance and adipogenic transformation of hepatocytes. | Larter CZ et al. | β | 2008 | β |
| Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. | Marra F et al. | β | 2008 | β |
| Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis. | Anderson N et al. | β | 2008 | β |
| Nonalcoholic fatty liver disease: pathogenesis and potential for nuclear receptors as therapeutic targets. | George J et al. | β | 2008 | β |
| [Nonalcoholic steatohepatitis: pathogenesis and treatment]. | Park SH | β | 2008 | β |
| Phyllanthus urinaria ameliorates the severity of nutritional steatohepatitis both in vitro and in vivo. | Shen B et al. | β | 2008 | β |
| Polaprezinc attenuates liver fibrosis in a mouse model of non-alcoholic steatohepatitis. | Sugino H et al. | β | 2008 | β |
| Redox mechanisms in hepatic chronic wound healing and fibrogenesis. | Novo E et al. | β | 2008 | β |
| Regulatable fatty acid transport mechanisms are central to the pathophysiology of obesity, fatty liver, and metabolic syndrome. | Berk PD | β | 2008 | β |
| Review article: current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. | Younossi ZM | β | 2008 | β |
| Role of CYP2E1 in thioacetamide-induced mouse hepatotoxicity. | Kang JS et al. | β | 2008 | β |
| Serum retinol binding protein 4 and nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. | Wu H et al. | β | 2008 | β |
| Small intestinal bacteria overgrowth decreases small intestinal motility in the NASH rats. | Wu WC et al. | β | 2008 | β |
| Temporary consumption of diet with unbalanced amino acid pattern affects long-lasting growth retardation correlated with oxidative stress response associated gene expression in juvenile pigs. | Schwerin M et al. | β | 2008 | β |
| The pathogenesis of ethanol versus methionine and choline deficient diet-induced liver injury. | Gyamfi MA et al. | β | 2008 | β |
| The transition from fatty liver to NASH associates with SAMe depletion in db/db mice fed a methionine choline-deficient diet. | Wortham M et al. | β | 2008 | β |
| The treatment with antibody of TNF-alpha reduces the inflammation, necrosis and fibrosis in the non-alcoholic steatohepatitis induced by methionine- and choline-deficient diet. | Koca SS et al. | β | 2008 | β |
| Transcriptomic analysis reveals early signs of liver toxicity in female MRL +/+ mice exposed to the acylating chemicals dichloroacetyl chloride and dichloroacetic anhydride. | KΓΆnig R et al. | β | 2008 | β |
| Acute ethanol pretreatment increases FAS-mediated liver injury in mice: role of oxidative stress and CYP2E1-dependent and -independent pathways. | Wang X et al. | β | 2007 | β |
| [Can metabolic steatohepatitis be treated?]. | Ratziu V et al. | β | 2007 | β |
| CCAAT/enhancing binding protein beta deletion in mice attenuates inflammation, endoplasmic reticulum stress, and lipid accumulation in diet-induced nonalcoholic steatohepatitis. | Rahman SM et al. | β | 2007 | β |
| Current concepts in the pathogenesis of nonalcoholic fatty liver disease. | MΓ©ndez-SΓ‘nchez N et al. | β | 2007 | β |
| Essential pathogenic and metabolic differences in steatosis induced by choline or methione-choline deficient diets in a rat model. | VetelΓ€inen R et al. | β | 2007 | β |
| Expression and activity of the cytochrome P450 2E1 in patients with nonalcoholic steatosis and steatohepatitis. | Chtioui H et al. | β | 2007 | β |
| Genomic profiling in nuclear receptor-mediated toxicity. | Woods CG et al. | β | 2007 | β |
| Hypoadiponectinemia accelerates hepatic tumor formation in a nonalcoholic steatohepatitis mouse model. | Kamada Y et al. | β | 2007 | β |
| Importance of PPAR alpha for the effects of growth hormone on hepatic lipid and lipoprotein metabolism. | Ljungberg A et al. | β | 2007 | β |
| Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. | Yamaguchi K et al. | β | 2007 | β |
| Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis. | Ota T et al. | β | 2007 | β |
| Insulin resistance in hepatocytes and sinusoidal liver cells: mechanisms and consequences. | Leclercq IA et al. | β | 2007 | β |
| Intrahepatic insulin resistance in a murine model of steatohepatitis: effect of PPARgamma agonist pioglitazone. | Leclercq IA et al. | β | 2007 | β |
| Iron preloading aggravates nutritional steatohepatitis in rats by increasing apoptotic cell death. | Imeryuz N et al. | β | 2007 | β |
| Kinase-dependent pathways and the development of insulin resistance in hepatocytes. | Rondinone CM | β | 2007 | β |
| Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet. | Matsuzawa N et al. | β | 2007 | β |
| Lipoprotein lipase activator ameliorates the severity of dietary steatohepatitis. | Yu J et al. | β | 2007 | β |
| Mild steatosis impairs functional recovery after liver resection in an experimental model. | VetelΓ€inen R et al. | β | 2007 | β |
| Modification of CYP2E1 and CYP3A4 activities in haemoglobin E-beta thalassemia patients. | Somparn N et al. | β | 2007 | β |
| N-acetylcysteine attenuates oxidative stress and liver pathology in rats with non-alcoholic steatohepatitis. | Thong-Ngam D et al. | β | 2007 | β |
| NADPH oxidase is not an essential mediator of oxidative stress or liver injury in murine MCD diet-induced steatohepatitis. | dela PeΓ±a A et al. | β | 2007 | β |
| Noninvasive assessment of fibrosis in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). | Miele L et al. | β | 2007 | β |
| Not all models of fatty liver are created equal: understanding mechanisms of steatosis development is important. | Larter CZ | β | 2007 | β |
| Pathogenesis of NASH: animal models. | London RM et al. | β | 2007 | β |
| Pathogenesis of non-alcoholic steatohepatitis: human data. | Edmison J et al. | β | 2007 | β |
| Polyunsaturated fat in the methionine-choline-deficient diet influences hepatic inflammation but not hepatocellular injury. | Lee GS et al. | β | 2007 | β |
| Preventive role of genistein in an experimental non-alcoholic steatohepatitis model. | Yalniz M et al. | β | 2007 | β |
| Risk for nonalcoholic fatty liver disease in Hispanic youth with BMI > or =95th percentile. | QuirΓ³s-Tejeira RE et al. | β | 2007 | β |
| Role of adipocytokines in hepatic fibrogenesis. | Ikejima K et al. | β | 2007 | β |
| Serotonin mediates oxidative stress and mitochondrial toxicity in a murine model of nonalcoholic steatohepatitis. | Nocito A et al. | β | 2007 | β |
| Severe steatosis increases hepatocellular injury and impairs liver regeneration in a rat model of partial hepatectomy. | VetelΓ€inen R et al. | β | 2007 | β |
| Steatosis as a risk factor in liver surgery. | VetelΓ€inen R et al. | β | 2007 | β |
| The 2006 Bernard B. Brodie Award Lecture. Cyp2e1. | Gonzalez FJ | β | 2007 | β |
| The role of the nuclear receptor constitutive androstane receptor in the pathogenesis of non-alcoholic steatohepatitis. | Yamazaki Y et al. | β | 2007 | β |
| Transgenic mice expressing nuclear sterol regulatory element-binding protein 1c in adipose tissue exhibit liver histology similar to nonalcoholic steatohepatitis. | Nakayama H et al. | β | 2007 | β |
| Adaptive failure to high-fat diet characterizes steatohepatitis in Alms1 mutant mice. | Arsov T et al. | β | 2006 | β |
| Additive effects of moderate drinking and obesity on serum gamma-glutamyl transferase activity. | Puukka K et al. | β | 2006 | β |
| Adenovirus-mediated expression of CYP2E1 produces liver toxicity in mice. | Bai J et al. | β | 2006 | β |
| Apoptosis in liver disease. | Schattenberg JM et al. | β | 2006 | β |
| A targeted apoB38.9 mutation in mice is associated with reduced hepatic cholesterol synthesis and enhanced lipid peroxidation. | Lin X et al. | β | 2006 | β |
| Combined effects of high-fat diet and ethanol induce oxidative stress in rat liver. | Demori I et al. | β | 2006 | β |
| Conditional deletion of beta-catenin reveals its role in liver growth and regeneration. | Tan X et al. | β | 2006 | β |
| COX-2 induction in mice with experimental nutritional steatohepatitis: Role as pro-inflammatory mediator. | Yu J et al. | β | 2006 | β |
| CYP2E1--biochemical and toxicological aspects and role in alcohol-induced liver injury. | Cederbaum AI | β | 2006 | β |
| Defective hepatic regeneration after partial hepatectomy in leptin-deficient mice is not rescued by exogenous leptin. | Leclercq IA et al. | β | 2006 | β |
| Dietary inulin alleviates hepatic steatosis and xenobiotics-induced liver injury in rats fed a high-fat and high-sucrose diet: association with the suppression of hepatic cytochrome P450 and hepatocyte nuclear factor 4alpha expression. | Sugatani J et al. | β | 2006 | β |
| Functional polymorphism in porcine CYP2E1 gene: Its association with skatole levels. | Lin Z et al. | β | 2006 | β |
| High-fat emulsion-induced rat model of nonalcoholic steatohepatitis. | Zou Y et al. | β | 2006 | β |
| How dietary arachidonic- and docosahexaenoic- acid rich oils differentially affect the murine hepatic transcriptome. | Berger A et al. | β | 2006 | β |
| Identification of longevity-associated genes in long-lived Snell and Ames dwarf mice. | Boylston WH et al. | β | 2006 | β |
| Insulin resistance, adiponectin, cytokines in NASH: Which is the best target to treat? | Larter CZ et al. | β | 2006 | β |
| JNK1 but not JNK2 promotes the development of steatohepatitis in mice. | Schattenberg JM et al. | β | 2006 | β |
| Liver disease in patients with diabetes mellitus. | Harrison SA | β | 2006 | β |
| Mice fed a lipogenic methionine-choline-deficient diet develop hypermetabolism coincident with hepatic suppression of SCD-1. | Rizki G et al. | β | 2006 | β |
| Mice heterozygous for the Mdr2 gene demonstrate decreased PEMT activity and diminished steatohepatitis on the MCD diet. | Igolnikov AC et al. | β | 2006 | β |
| Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. | Begriche K et al. | β | 2006 | β |
| Nonalcoholic fatty liver disease: Cytokine-adipokine interplay and regulation of insulin resistance. | Tilg H et al. | β | 2006 | β |
| Nonalcoholic fatty liver disease: from steatosis to cirrhosis. | Farrell GC et al. | β | 2006 | β |
| Non-alcoholic steatohepatitis: from cell biology to clinical practice. | Cortez-Pinto H et al. | β | 2006 | β |
| Potential impact of steatosis on cytochrome P450 enzymes of human hepatocytes isolated from fatty liver grafts. | Donato MT et al. | β | 2006 | β |
| Rodent nutritional model of steatohepatitis: effects of endotoxin (lipopolysaccharide) and tumor necrosis factor alpha deficiency. | Kirsch R et al. | β | 2006 | β |
| Roles of phosphatidylinositol 3-kinase and osteopontin in steatosis and aminotransferase release by hepatocytes treated with methionine-choline-deficient medium. | Sahai A et al. | β | 2006 | β |
| Transcription factor Nrf2 protects HepG2 cells against CYP2E1 plus arachidonic acid-dependent toxicity. | Gong P et al. | β | 2006 | β |
| Tumour necrosis factor alpha signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice. | Tomita K et al. | β | 2006 | β |
| Acetoacetate induces CYP2E1 protein and suppresses CYP2E1 mRNA in primary cultured rat hepatocytes. | Abdelmegeed MA et al. | β | 2005 | β |
| A high-fat diet leads to the progression of non-alcoholic fatty liver disease in obese rats. | Carmiel-Haggai M et al. | β | 2005 | β |
| Altered expression of cytochrome P450 and possible correlation with preneoplastic changes in early stage of rat hepatocarcinogenesis. | Liu LL et al. | β | 2005 | β |
| Chronic ethanol feeding and folate deficiency activate hepatic endoplasmic reticulum stress pathway in micropigs. | Esfandiari F et al. | β | 2005 | β |
| CYP2E1-dependent hepatotoxicity and oxidative damage after ethanol administration in human primary hepatocytes. | Liu LG et al. | β | 2005 | β |
| CYP2E1-dependent oxidative stress and toxicity: role in ethanol-induced liver injury. | Jimenez-Lopez JM et al. | β | 2005 | β |
| Cytochrome P4502E1 primes macrophages to increase TNF-alpha production in response to lipopolysaccharide. | Cao Q et al. | β | 2005 | β |
| Cytochrome P450 CYP2E1, but not nicotinamide adenine dinucleotide phosphate oxidase, is required for ethanol-induced oxidative DNA damage in rodent liver. | Bradford BU et al. | β | 2005 | β |
| Hepatic gene expression in patients with obesity-related non-alcoholic steatohepatitis. | Younossi ZM et al. | β | 2005 | β |
| Hepatocyte CYP2E1 overexpression and steatohepatitis lead to impaired hepatic insulin signaling. | Schattenberg JM et al. | β | 2005 | β |
| High glucose stimulates hepatic stellate cells to proliferate and to produce collagen through free radical production and activation of mitogen-activated protein kinase. | Sugimoto R et al. | β | 2005 | β |
| Immune response towards lipid peroxidation products as a predictor of progression of non-alcoholic fatty liver disease to advanced fibrosis. | Albano E et al. | β | 2005 | β |
| Increased lipopolysaccharide sensitivity in alcoholic fatty livers is independent of leptin deficiency and toll-like receptor 4 (TLR4) or TLR2 mRNA expression. | Romics L et al. | β | 2005 | β |
| Increase in liver antioxidant enzyme activities in non-alcoholic fatty liver disease. | Perlemuter G et al. | β | 2005 | β |
| Induction of cytochrome P450 2E1 increases hepatotoxicity caused by Fas agonistic Jo2 antibody in mice. | Wang X et al. | β | 2005 | β |
| Liver-specific inactivation of the Nrf1 gene in adult mouse leads to nonalcoholic steatohepatitis and hepatic neoplasia. | Xu Z et al. | β | 2005 | β |
| Measurement of the total antioxidant response using a novel automated method in subjects with nonalcoholic steatohepatitis. | Horoz M et al. | β | 2005 | β |
| NF-kappaB activation, rather than TNF, mediates hepatic inflammation in a murine dietary model of steatohepatitis. | Dela PeΓ±a A et al. | β | 2005 | β |
| Nonalcoholic fatty liver disease: a clinical review. | Sass DA et al. | β | 2005 | β |
| Nrf1 gene expression in the liver: a single gene linking oxidative stress to NAFLD, NASH and hepatic tumours. | Maurizio P et al. | β | 2005 | β |
| [Pathogenesis of primary nonalcoholic fatty liver disease]. | Moreno SΓ‘nchez D | β | 2005 | β |
| Pathophysiological basis for antioxidant therapy in chronic liver disease. | Medina J et al. | β | 2005 | β |
| Pretranslational upregulation of microsomal CYP4A in rat liver by intake of a high-sucrose, lipid-devoid diet containing orotic acid. | Su GM et al. | β | 2005 | β |
| Review article: the pathogenesis of fibrosis in non-alcoholic steatohepatitis. | Marra F et al. | β | 2005 | β |
| Role of cytochromes P450 in chemical toxicity and oxidative stress: studies with CYP2E1. | Gonzalez FJ | β | 2005 | β |
| Serum iron levels and hepatic iron overload in nonalcoholic steatohepatitis and chronic viral hepatitis. | Uraz S et al. | β | 2005 | β |
| Steatohepatitis develops rapidly in transgenic mice overexpressing Abcb11 and fed a methionine-choline-deficient diet. | Sundaram SS et al. | β | 2005 | β |
| Steatohepatitis induced by intragastric overfeeding in mice. | Deng QG et al. | β | 2005 | β |
| Systemic markers of lipid peroxidation and antioxidants in patients with nonalcoholic Fatty liver disease. | Yesilova Z et al. | β | 2005 | β |
| Acarbose attenuates experimental non-alcoholic steatohepatitis. | Lieber CS et al. | β | 2004 | β |
| Acetoacetate activation of extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase in primary cultured rat hepatocytes: role of oxidative stress. | Abdelmegeed MA et al. | β | 2004 | β |
| Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice. | Ip E et al. | β | 2004 | β |
| Animal models of nonalcoholic fatty liver disease and steatohepatitis. | Nanji AA | β | 2004 | β |
| Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis. | Medina J et al. | β | 2004 | β |
| Curcumin inhibits NF-kappaB activation and reduces the severity of experimental steatohepatitis in mice. | Leclercq IA et al. | β | 2004 | β |
| CYP2E1 overexpression alters hepatocyte death from menadione and fatty acids by activation of ERK1/2 signaling. | Schattenberg JM et al. | β | 2004 | β |
| Hepatic microvascular dysfunction during evolution of dietary steatohepatitis in mice. | McCuskey RS et al. | β | 2004 | β |
| Hepatic steatosis in obese patients: clinical aspects and prognostic significance. | Festi D et al. | β | 2004 | β |
| Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms. | Ingelman-Sundberg M | β | 2004 | β |
| Identification of oxidized mitochondrial proteins in alcohol-exposed human hepatoma cells and mouse liver. | Suh SK et al. | β | 2004 | β |
| [Insulin resistance. A cause or consequence of liver disease?]. | Vargas V | β | 2004 | β |
| Insulin resistance and the pathogenesis of nonalcoholic fatty liver disease. | Choudhury J et al. | β | 2004 | β |
| Mitochondrial injury in steatohepatitis. | Pessayre D et al. | β | 2004 | β |
| Model of nonalcoholic steatohepatitis. | Lieber CS et al. | β | 2004 | β |
| Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. | Harrison SA et al. | β | 2004 | β |
| Nonalcoholic fatty liver disease: a review of current understanding and future impact. | Charlton M | β | 2004 | β |
| Nonalcoholic Steatohepatitis. | Mulhall BP et al. | β | 2004 | β |
| Non-alcoholic steatohepatitis in the Asia-Pacific region: future shock? | Chitturi S et al. | β | 2004 | β |
| Obese and diabetic db/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis: role of short-form leptin receptors and osteopontin. | Sahai A et al. | β | 2004 | β |
| Oxidative stress, toxicology, and pharmacology of CYP2E1. | Caro AA et al. | β | 2004 | β |
| Pentoxifylline attenuates steatohepatitis induced by the methionine choline deficient diet. | Koppe SW et al. | β | 2004 | β |
| Role of oxidative stress in the increased activation of signal transducers and activators of transcription-3 in the fatty livers of obese Zucker rats. | Dikdan GS et al. | β | 2004 | β |
| Sex differences in choline-deficient diet-induced steatohepatitis in mice. | Kashireddy PR et al. | β | 2004 | β |
| The ins and outs of mitochondrial dysfunction in NASH. | Fromenty B et al. | β | 2004 | β |
| The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance. | Rinella ME et al. | β | 2004 | β |
| Upregulation of osteopontin expression is involved in the development of nonalcoholic steatohepatitis in a dietary murine model. | Sahai A et al. | β | 2004 | β |
| Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor gamma1 (PPARgamma1) overexpression. | Yu S et al. | β | 2003 | β |
| Advances in the understanding and treatment of nonalcoholic fatty liver disease. | Harrison SA et al. | β | 2003 | β |
| Alcohol metabolism: role in toxicity and carcinogenesis. | Badger TM et al. | β | 2003 | β |
| A new approach to drug therapy in non-alcoholic steatohepatitis (NASH). | FehΓ©r J et al. | β | 2003 | β |
| Binge ethanol exposure increases liver injury in obese rats. | Carmiel-Haggai M et al. | β | 2003 | β |
| Central role of PPARalpha-dependent hepatic lipid turnover in dietary steatohepatitis in mice. | Ip E et al. | β | 2003 | β |
| Current best treatment for non-alcoholic fatty liver disease. | Angulo P | β | 2003 | β |
| CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease. | Emery MG et al. | β | 2003 | β |
| Cytochrome P450: major player in reperfusion injury. | Gottlieb RA | β | 2003 | β |
| Diabetes mellitus increases the in vivo activity of cytochrome P450 2E1 in humans. | Wang Z et al. | β | 2003 | β |
| Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. | Chalasani N et al. | β | 2003 | β |
| Hepatic gene expression in histologically progressive nonalcoholic steatohepatitis. | Sreekumar R et al. | β | 2003 | β |
| Hydroperoxy-10,12-octadecadienoic acid stimulates cytochrome P450 3A protein aggregation by a mechanism that is inhibited by substrate. | Kimzey AL et al. | β | 2003 | β |
| Inhibition of microsomal triglyceride transfer protein: another mechanism for drug-induced steatosis in mice. | LettΓ©ron P et al. | β | 2003 | β |
| Lipid peroxidation, stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitis. | George J et al. | β | 2003 | β |
| NASH--hepatic metabolism and not simply the metabolic syndrome. | Green RM | β | 2003 | β |
| Non-alcoholic fatty liver: a common manifestation of a metabolic disorder. | Malnick SD et al. | β | 2003 | β |
| Non-alcoholic steatohepatitis: what is it, and why is it important in the Asia-Pacific region? | Farrell GC | β | 2003 | β |
| Oxidative stress, KLF6 and transforming growth factor-beta up-regulation differentiate non-alcoholic steatohepatitis progressing to fibrosis from uncomplicated steatosis in rats. | StΓ€rkel P et al. | β | 2003 | β |
| Relationship between genetic polymorphism of cytochrome P450IIE1 and fatty liver. | Piao YF et al. | β | 2003 | β |
| Review article: Non-alcoholic fatty liver disease. | Alba LM et al. | β | 2003 | β |
| Rodent nutritional model of non-alcoholic steatohepatitis: species, strain and sex difference studies. | Kirsch R et al. | β | 2003 | β |
| The combined effects of garlic oil and fish oil on the hepatic antioxidant and drug-metabolizing enzymes of rats. | Chen HW et al. | β | 2003 | β |
| Blocking the secretion of hepatic very low density lipoproteins renders the liver more susceptible to toxin-induced injury. | BjΓΆrkegren J et al. | β | 2002 | β |
| Cytochrome P450 2E1-derived reactive oxygen species mediate paracrine stimulation of collagen I protein synthesis by hepatic stellate cells. | Nieto N et al. | β | 2002 | β |
| Dietary protein modifies hepatic gene expression associated with oxidative stress responsiveness in growing pigs. | Schwerin M et al. | β | 2002 | β |
| Diverse roles of the nuclear orphan receptor CAR in regulating hepatic genes in response to phenobarbital. | Ueda A et al. | β | 2002 | β |
| Dolichol content in isolated sinusoidal liver cells after in vivo chronic treatment with thioacetamide. | Nanni G et al. | β | 2002 | β |
| Excess alcohol greatly increases the prevalence of cirrhosis in hereditary hemochromatosis. | Fletcher LM et al. | β | 2002 | β |
| Gliclazide-induced acute hepatitis with hypersensitivity features. | Chitturi S et al. | β | 2002 | β |
| Hepatic steatosis and liver transplantation current clinical and experimental perspectives. | Koneru B et al. | β | 2002 | β |
| Increased cytochrome P-450 2E1 expression sensitizes hepatocytes to c-Jun-mediated cell death from TNF-alpha. | Liu H et al. | β | 2002 | β |
| Induction and regulation of hepatocyte apoptosis by oxidative stress. | Czaja MJ | β | 2002 | β |
| Leptin is essential for the hepatic fibrogenic response to chronic liver injury. | Leclercq IA et al. | β | 2002 | β |
| Liver disease in the elderly. | Jansen PL | β | 2002 | β |
| Liver regeneration in obese mice with fatty livers: does the impairment have relevance for other types of fatty liver disease? | Farrell GC et al. | β | 2002 | β |
| Nonalcoholic fatty liver disease. | Angulo P | β | 2002 | β |
| Non-alcoholic fatty liver disease: an overview. | Mulhall BP et al. | β | 2002 | β |
| Non-alcoholic steatohepatitis: definitions and pathogenesis. | Day CP et al. | β | 2002 | β |
| Non-alcoholic steatohepatitis (NASH): where are we now and where are we going? | Day CP | β | 2002 | β |
| Nonalcoholic steatohepatitis: what we know in the new millennium. | Harrison SA et al. | β | 2002 | β |
| Nonalcoholic steatosis and steatohepatitis. V. Mitochondrial dysfunction in steatohepatitis. | Pessayre D et al. | β | 2002 | β |
| Novel roles of liver X receptors exposed by gene expression profiling in liver and adipose tissue. | Stulnig TM et al. | β | 2002 | β |
| Pathogenesis of steatohepatitis. | Day CP | β | 2002 | β |
| Risk of HAART therapy in hepatitis C. | McGovern B et al. | β | 2002 | β |
| S-Adenosylmethionine: a control switch that regulates liver function. | Mato JM et al. | β | 2002 | β |
| Spontaneous oxidative stress and liver tumors in mice lacking methionine adenosyltransferase 1A. | MartΓnez-Chantar ML et al. | β | 2002 | β |
| The clinicopathologic spectrum and management of nonalcoholic fatty liver disease. | Contos MJ et al. | β | 2002 | β |
| The metabolic abnormalities associated with non-alcoholic fatty liver disease. | Haque M et al. | β | 2002 | β |
| Treatment of nonalcoholic fatty liver disease. | Angulo P | β | 2002 | β |
| Treatment of non-alcoholic steatohepatitis. | Angulo P et al. | β | 2002 | β |
| Update on nonalcoholic fatty liver disease. | McCullough AJ | β | 2002 | β |
| Alcoholic liver disease: a matter of hormones? | Moshage H | β | 2001 | β |
| Effect of beta-carotene on hepatic cytochrome P-450 in ethanol-fed rats. | Kessova IG et al. | β | 2001 | β |
| Insulin resistance and mitochondrial abnormalities in NASH: a cool look into a burning issue. | Angulo P et al. | β | 2001 | β |
| Is bacterial ash the flash that ignites NASH? | Farrell GC | β | 2001 | β |
| Lipoprotein secretion and triglyceride stores in the heart. | Bjorkegren J et al. | β | 2001 | β |
| Nonalcoholic steatohepatitis. | Reid AE | β | 2001 | β |
| Nonalcoholic steatosis and steatohepatitis. II. Cytochrome P-450 enzymes and oxidative stress. | Robertson G et al. | β | 2001 | β |
| Oxidative stress-related molecules and liver fibrosis. | Parola M et al. | β | 2001 | β |
| Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy. | Ingelman-Sundberg M | β | 2001 | β |
| The use of gene knockout mice to unravel the mechanisms of toxicity and chemical carcinogenesis. | Gonzalez FJ | β | 2001 | β |
| Two dimensional non equilibrium pH gel electrophoresis mapping of cytosolic protein changes caused by dietary protein depletion in mouse liver. | Sanllorenti PM et al. | β | 2001 | β |
| The alcohol-inducible form of cytochrome P450 (CYP 2E1): role in toxicology and regulation of expression. | Novak RF et al. | β | 2000 | β |